Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is characterized by the degeneration of both upper and lower motor neurons, which leads to muscle weakness and eventual paralysis. Until recently, ALS was classified primarily within the neuromuscular domain, although new imaging and neuropathological data have indicated the involvement of the non-motor neuraxis in disease pathology. In most patients, the mechanisms underlying the development of ALS are poorly understood, although a subset of patients have familial disease and harbour mutations in genes that have various roles in neuronal function. Two possible disease-modifying therapies that can slow disease progression are available…

• EL
  Eli Lilly and Company
• G
  GlaxoSmithKline
• S
  Sanofi
• B
  Biogen
• B
  Baxalta
• EJ
  EU Joint Programme – Neurodegenerative Disease Research
• C
  Cytokinetics
• SF
  Science Foundation Ireland
• MT
  Mitsubishi Tanabe Pharma Corporation
• SA
  Stichting ALS Nederland
• I
  Italfarmaco
• MR
  Medical Research Council

  Award: MR/L501529/1